Semaglutide (sodium salt) Datasheet | DC12282

Semaglutide (sodium salt) — Datasheet

CAT. NO. DC12282

Parameter	Value
Chemical Name	Semaglutide
CAS No.	910463-68-2
Synonyms	索玛鲁肽;Sermaglutide;Semaglutide;Unknown (acetate);NN9535;Semaglutide [USAN:INN];Ozempic;NN 9535;Rybelsus (oral semaglutide);GTPL9724;Ozempic (injectable semaglutide);semaglutide/Sermaglutide;A10BJ06;A10BJ06;NNC0480 0389;NNC0480 0389;CHEBI:167574;CHEBI:167574;Rybelsus;Ozempic;NN9535;OG217SC;NNC 0113-0217;Rybelsus;Ozempic;NN9535;OG217SC;NNC 0113-0217;semaglutida;semaglutida;AC-32580;AC-32580;Rybelsus;Rybelsus;Wegovy;Wegovy;UNII-53AXN4NNHX;UNII-53AXN4NNHX;53AXN4NNHX;53AXN4NNHX;910463-68-2;910463-68-2;Semaglutide free base;Semaglutide free base;SEMAGLUTIDE COMPONENT OF NN1535 ICOSEMA;SEMAGLUTIDE COMPONENT OF NN1535 ICOSEMA;DTXSID101027903;DTXSID101027903;semaglutidum;semaglutidum;NNC 0113-0217;NNC 0113-0217;NN1535 ICOSEMA COMPONENT SEMAGLUTIDE;NN1535 ICOSEMA COMPONENT SEMAGLUTIDE;NN1535 LAISEMA COMPONENT SEMAGLUTIDE;NN1535 LAISEMA COMPONENT SEMAGLUTIDE;NN-9535;NN-9535;EX-A2424;EX-A2424;Semaglutide(sodium salt)?;Semaglutide(sodium salt)?;NNC-0113-0217;Oral Semaglutide;NNC-0113-0217;Oral Semaglutide
Formula	C187H291N45O59
M.Wt	4113.64
SMILES	O=C([C@H](CC(C)C)NC([C@H](CC1=CNC2=CC=CC=C12)NC([C@H](C)NC([C@H]([C@@H](C)CC)NC([C@H](CC1C=CC=CC=1)NC([C@H](CCC(=O)O)NC([C@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](C(=O)O)NC(CCCCCCCCCCCCCCCCC(=O)O)=O)=O)=O)=O)NC([C@H](C)NC([C@H](C)NC([C@H](CCC(N)=O)NC(CNC([C@H](CCC(=O)O)NC([C@H](CC(C)C)NC([C@H](CC1C=CC(=CC=1)O)NC([C@H](CO)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CC(=O)O)NC([C@H](CO)NC([C@H]([C@@H](C)O)NC([C@H](CC1C=CC=CC=1)NC([C@H]([C@@H](C)O)NC(CNC([C@H](CCC(=O)O)NC(C(C)(C)NC([C@H](CC1=CN=CN1)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(=O)O)=O)CCCNC(=N)N)=O)=O)CCCNC(=N)N)=O)C(C)C
Purity	>98%
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes.

In Vitro

Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38±0.06 nM[1]. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1[3.

In Vivo

The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs[1]. Semaglutide improves 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairments. In addition, Semaglutide rescues the decrease of tyrosine hydroxylase (TH) levels, alleviates the inflammation response, reduces lipid peroxidation, inhibits the apoptosis pathway, and also increases autophagy- related protein expression, to protect dopaminergic neurons in the substantia nigra and striatum. Moreover, the long-acting GLP-1 analogue semaglutide is superior to liraglutide in most parameters[2]. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight[3].

Target

GLP-1 receptor[1].

Animal Administration

Mice[2] Male C57BL/6 mice 10 weeks old (20-25 g) are used throughout the study. Mice are randomized divided into six groups (n=12 per group) (i) control group treated with saline alone; (ii) liraglutide group treated with saline and liraglutide (25 nmol/kg ip. once daily for 7 days); (iii) Semaglutide group treated with saline and Semaglutide (25 nmol/kg ip. once daily for 7 days), (iv) MPTP group treated with MPTP alone (once daily 20 mg/kg ip. for 7 days); (v) MPTP (once daily 20 mg/kg ip. for 7 days) followed immediately by liraglutide treated group (25 nmol/kg ip. once daily for 7 days). (vi) MPTP (20 mg/kg ip. once daily for 7 days) followed immediately by Semaglutide treated group (25 nmol/kg ip. Once daily for 7 days). At the end of drug treatments, measure the behavioral changes, neuronal damage, inflammatory markers, and other biomarkers[2].

References & source

[1]. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844.

[2]. Zhang L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model. Neuropeptides. 2018 Oct;71:70-80.

[3]. Dhillon S, et al. Semaglutide: First Global Approval. Drugs. 2018 Feb;78(2):275-284.

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.